Escaping the Current Gaps in the Understanding and Treatment of CKD Anemia: Making Sense of Emerging Therapies
Supported by an educational grant from GSK
Click Here to Manage Email Alerts
This activity is jointly provided by Partners for Advancing Clinical Education and Cardiometabolic Health Congress.
Supported by an educational grant from GSK
Program Overview:
Release Date: January 27, 2023
Expiration Date:January 27, 2024
Anemia is a common comorbidity in patients with chronic kidney disease (CKD), and is associated with significant morbidity and impacts on quality of life. The complicated pathophysiology of the condition and the disadvantages associated with current treatments are some of the major barriers that clinicians face in reducing the burden of anemia in patients with CKD. Because of the low treatment rates for renal anemia, clinicians who treat patients with cardio-renal syndrome, including nephrologists, cardiologists, PCPs and others, need to be aware of the current treatments and guideline recommendations in this setting. Furthermore, due to the need for additional treatments, several agents are in advanced clinical development and have shown promising results, albeit with important differences among them. This symposium will cover the burden, screening, current treatments, as well as emerging treatment options for renal anemia.
Learning Objectives:
After completing this activity, the participant should be better able to:
- Review the burden, risk factors, and pathophysiology of anemia in CKD
- List current approaches for the screening and diagnosis of anemia in CKD patients
- Summarize current treatment options for anemia of CKD and challenges associated with their use
- Review the role of emerging treatment options in addressing current treatment gaps for anemia in CKD
Chair
Ajay K. Singh, MBBS, FRCP (UK), MBA
Senior Associate Dean for Postgraduate Medical Education
Director, Master in Medical Sciences in Clinical Investigation (MMSCI) program
Physician, Renal Division, Harvard Medical School
Brigham and Women’s Hospital/ Dana Farber Cancer Institute
Boston, MA
Dr. Singh discloses the following:
Consultant, Advisor, Speaker: GSK, Bayer, Zydus, Nephrology Times
Faculty
Bradley Denker, MD
Clinical Chief, Renal Division, Beth Israel Deaconess Medical Center
Boston, MA
Dr. Denker has no relevant financial relationship(s) with ineligible companies to disclose.
Romela Petrosyan, MD
Nephrologist and Proceduralist, Renal Division, Brigham and Women's Hospital
Boston, MA
Dr. Petrosyan has no relevant financial relationship(s) with ineligible companies to disclose.
JOINT PROVIDERSHIP STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
PHARMACY CONTINUING EDUCATION
PACE designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-23-022-H01-P. Type of activity: Application
DIETITIAN CONTINUING EDUCATION
This program offers 1.0 CPEUs for dietitians.
Instructions for Participation
In order to receive credit, participants must complete the activity in its entirety. Participants must also score at least a 75% on the posttest and submit it, along with the credit application and evaluation form.
There are no fees for participating in this activity.
For additional information about the accreditation of this activity, please visit https://partnersed.com
DISCLOSURES
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The CMHC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
DISCLOSURE OF CONFLICT OF INTEREST
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities